anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tropomyosin (Tpm) is a regulatory actin-binding protein involved in Ca2+ activation of contraction of striated muscle. In human slow skeletal muscles, two distinct Tpm isoforms, γ and β, are present. They interact to form three types of dimeric Tpm molecules: γγ-homodimers, γβ-heterodimers, or ββ-homodimers, and a majority of the molecules are present as γβ-Tpm heterodimers. Point mutation R91P within the TPM3 gene encoding γ-Tpm is linked to the condition known as congenital fiber-type disproportion (CFTD), which is characterized by severe muscle weakness. Here, we investigated the influence of the R91P mutation in the γ-chain on the properties of the γβ-Tpm heterodimer. We found that the R91P mutation impairs the functional properties of γβ-Tpm heterodimer more severely than those of earlier studied γγ-Tpm homodimer carrying this mutation in both γ-chains. Since a significant part of Tpm molecules in slow skeletal muscle is present as γβ-heterodimers, our results explain why this mutation leads to muscle weakness in CFTD.
PURPOSE: A compound which contains radioactive isotopes and paramagnetic elements and is used as a single photon emission computed tomography/magnetic resonance imaging (SPECT/MRI) dual contrast agent is provided to be used as a contrast agent for MRI and a nuclear medical imaging instrument without toxicity to human body and to effectively diagnose cancer. CONSTITUTION: A compound is denoted by chemical formula 1. The compound has a structure of chemical formula 1a. A method for preparing the compound comprises the steps of: reacting a compound of chemical formula 3 with a compound of chemical formula 4; and labeling a meta site of tyrosine of Arg-Gly-Asp (RGD) with iodine. A gadolinium precursor is Gd (III)X_3. A SPECT contrast agent contains the compound. A SPECT/MRI dual contrast agent contains the compound. [Reference numerals] (AA,BB) Ligand
The individuals in the second group will be asked to do the home exercise program shown to them for 4 weeks, 3 days a week. Individuals included in this group will be given a program that includes stretching and posture exercises for the same muscle groups. Individuals in the control group will be called weekly during the 4-week period. Before, after, and 6 weeks after the study, re-evaluation parameters will be applied to all individuals included in the study.
Methods and compositions for targeting of pharmaceuticals or other therapeutics to specific tissues using tissue-specific endothelial membrane proteins are provided. The compositions comprise a therapeutic complex composed of a ligand, a linker, and a therapeutic moiety, where the therapeutic moiety can enter the cell. The ligand can be an antibody or other molecule that binds to a tissue-specific protein on the endothelial membrane of a specific tissue. The ligand need not activate a receptor, but may activate endocytosis. The therapeutic moiety can be a drug, gene, antisense oligonucleotide, contrast agent, protein, toxin, or any type of molecule that acts on the specific tissue. The linker can be a liposome or a cleavable or noncleavable chemical molecule. Alternatively, the linker may simply be the bond between the ligand and the therapeutic moiety. Alternatively, a lipophilic prodrug may be cleaved and may enter the cell due to its lipophilic properties.
A total of 701 patients with type 2 diabetes participated in a 24-week, randomized, double-blind, placebo-controlled study designed to assess the efficacy of linagliptin in combination with metformin. Patients already on metformin (n=491) at a dose of at least 1500 mg per day were randomized after completing a 2-week open-label placebo run-in period. Patients on metformin and another antihyperglycemic agent (n=207) were randomized after a run-in period of approximately 6 weeks on metformin (at a dose of at least 1500 mg per day) in monotherapy. Patients were randomized to the addition of either linagliptin 5 mg or placebo, administered once daily. Patients who failed to meet specific glycemic goals during the studies were treated with glimepiride rescue.

In combination with metformin, linagliptin provided statistically significant improvements in A1C, FPG, and 2-hour PPG compared with placebo (Table 8). Rescue glycemic therapy was used in 7.8% of patients treated with linagliptin 5 mg and in 18.9% of patients treated with placebo. A similar decrease in body weight was observed for both treatment groups.
Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion.
Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in children receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in children with resultant compromised adult height.

Seizures have been reported rarely with the institution of levothyroxine therapy.

Inadequate levothyroxine dosage will produce or fail to ameliorate the signs and symptoms of hypothyroidism.

Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various GI symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness and wheezing. Hypersensitivity to levothyroxine itself is not known to occur.
Nurr1 is a member of the orphan nuclear receptor family NR4A (nuclear receptor subfamily 4 group A) that modulates inflammation in several cell lineages, both positively and negatively. Macrophages are key regulators of inflammatory responses, yet information about the role of Nurr1 in human macrophages is scarce. Here we examined Nurr1 expression and activity in steady state and activated human macrophages. Pro- and anti-inflammatory macrophages were generated in vitro by culture of blood monocytes with granulocyte/macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF), respectively. Nurr1 expression was predominant in macrophages with the pro-inflammatory phenotype. Nurr1 activation with the agonists 1,1-bis(3'-indolyl)-1-(p-chlorophenyl) methane (C-DIM12) or isoxazolo-pyridinone 7e (IP7e) did not globally modify the polarization status of pro-inflammatory macrophages, but they decreased their production of TNF, IL-1β, IL-6, IL-8, IL-12 p40, CCL2, IFN-β, and reactive oxygen species, with variable potencies. Conversely, Nurr1 deficient macrophages increased the expression of transcripts encoding inflammatory mediators, particularly that of IL6, IFNB1, and CCL2. Mechanistically, endogenous Nurr1 interacted with NF-κB p65 in basal conditions and upon lipopolysaccharide (LPS)-mediated activation. C-DIM12 stabilized those complexes in cells exposed to LPS and concurrently decreased NF-κB transcriptional activity and p65 nuclear translocation. Expression of high levels of Nurr1 was associated with a subset of dermal macrophages that display enhanced levels of TNF and lower expression of the anti-inflammatory marker CD163L1 in skin lesions from patients with bullous pemphigoid (BP), a chronic inflammatory autoimmune blistering disorder. These results suggest that Nurr1 expression is linked with the pro-inflammatory phenotype of human macrophages, both in vivo and in vitro, where it may constitute a brake to attenuate the synthesis of inflammatory mediators.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, particularly ophthalmology, and concerns conservative treatment of pterygium. The preparation Alasens 15 mg/kg of weight is orally introduced in a patient. In 3 hours after introduction of the preparation, a pterygium area is once exposed to laser at wave length 635 nm at total power density 80-100 J/cm2. The exposure is continued to reduce intensity of the induced pterygium area to a level or lower than surrounding bulbar conjunctiva. ^ EFFECT: method provides effective conservative treatment of the disease, stabilising growth and promoting pterygium tissue regression, including due to obliteration of new vessels, while preserving eyeball tissues surrounding pterygium that allows avoiding surgical management of the disease. ^ 1 ex, 2 dwg
The invention is in the field of immunotherapy. The present application provides modified RELA protein which are useful for inducing or promoting interferon expression by immune cells, in particular T cells. The invention enables the production of immune cells with an activated or enhanced interferon metabolism. The present application also relates to immune cells, in particular T cells, comprising and/or expressing a modified RELA protein according to the invention, such cells having an activated interferon metabolism. The present invention also provides in vitro and/or ex vivo method of preparing immune cells, in particular T cells, useful in immunotherapy. The invention also relates to methods for treating a patient, in particular a patient who has a cancer or an infectious disease, in particular an infection by a virus.
Melatonin is a hormone secreted predominantly during the sleep period, suspected to have a strong link to the circadian sleep-wake cycle. Melatonin is also available in a pill form and, when administered during the day, tends to have a sedative effect. Clinical trials that have examined the nocturnal effects of melatonin have focused on patients of any age who have insomnia, regardless of their endogenous melatonin levels. Data indicate, however, that individuals with low endogenous melatonin levels may be more responsive to exogenous melatonin. Generally, melatonin levels decrease with age; therefore, older individuals with insomnia represent an ideal population in which to study the effects of exogenous melatonin on sleep. This study will provide older adults with insomnia melatonin tablets to determine whether the tablets will increase their sleep.

Participation in this study will last 10 weeks and will comprise overnight visits at 2 timepoints, the beginning of Week 1 and the end of Week 6. At study entry, participants will be admitted to the General Clinical Research Center for a 3-night stay, beginning with an overnight urine screen to confirm low melatonin levels. Participants will also be asked to begin a sleep diary documenting their sleep quality and quantity; the diary will be used throughout the study. During Night 1 at the clinic, participants will have urine samples collected throughout the night. Night 2 will be an adaptation night to allow participants to get used to their surroundings. On Night 3, participants will have sensors attached to their bodies and a polysomnograph machine will be used to measure their sleep efficiency. Participants with sleep efficiencies of 80% or higher will complete their study participation. Participants with sleep efficiencies less than 80% will be randomly assigned to one of three study treatments daily for 6 weeks: high-dose melatonin (4.0 mg), low-dose melatonin (0.4 mg), or placebo. Participants will have study visits at Weeks 1, 3, and 6 to monitor for adverse events. After 6 weeks, participants will have 2 more overnight clinic visits that will be identical to Nights 2 and 3 from the beginning of the study. Sleep questionnaires, cognitive tests, and psychomotor tests will be used to assess participants at the beginning of the study, after 6 weeks, and at the end of the study. One month after the end of the study, participants will have a follow-up visit to be reassessed for adverse events.
Study design is an evaluation of the STARSTIM device (tDCS) in subjects over 9 years of age, diagnosed with epilepsy with focal seizures with or without focal to bilateral tonic clonic seizures. Seizure diaries will be collected for 12 weeks to establish a rate of seizure for each subject prior to treatment. Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment. Neither the study investigator nor subject shall be notified of the treatment assignment. Treatment will be done daily at the investigator's site for 10 days. A Seizure Diary will be maintained through the course of the treatment and the follow up period. Subjects will have 3 follow up visits to evaluate their seizure rate, adverse events, medications and quality of life. A Data Safety Monitoring Board will be utilized to evaluate safety events through study milestones. Seizure frequency rates pre, during and post treatment will be evaluated for both the active and sham treatment arms.
The first intervention targets obstetric hemorrhage, severe hypertension and maternal health equity by implementing three relevant AIM bundles: Obstetric Hemorrhage, Severe Hypertension in Pregnancy, and Reduction of Peripartum Racial/Ethnic Disparities. The Perinatal Neonatal Quality Improvement Network (PNQIN) will facilitate this collaborative QI project and support participating hospitals by providing guidance, education, and technical assistance to hospitals to support implementation of bundles using the QI process. Implementation strategies are based on the Institute for Healthcare Improvement (IHI) improvement model and the AIM program implementation toolkit and have previously been used by PNQIN to implement the Obstetric Care for Women with Opioid Use Disorder AIM bundle in 22 hospitals, including the five hospitals for this study.
Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
Skin cancer is the most common cancer in Caucasians and therefore a major public health issue. Its incidence is increasing rapidly. Actinic keratosis (AK) is the most prevalent precancerous chronic skin condition. It can transform into squamous cell carcinoma (SCC). AK's generally arise in a skin area that has diffuse precancerous damage, a phenomenon called field cancerization. Because of its precancerous character, it is advised to treat AK and herewith prevent development into SCC. The most frequently used field-directed treatments in the Netherlands are photodynamic therapy (PDT), topical 5% f-fluorouracil (5% 5-FU) and topical 5% Imiquimod (5% IMI). Lately another topical product is approved by Dutch healthcare insurances: Ingenol mebutate (IM). Up to date, which treatment the patient will receive, does not rely on evidence-based-medicine, but generally on the preference of the physician. Current national and international guidelines state no clear recommendations for the best choice of therapy. The aim of this study determine which treatment is the most effective treatment in terms of lesion reduction, costs and patient satisfaction when comparing topical treatment with photodynamic therapy (PDT), 5% 5-fluorouracil (5-FU) cream, 5% Imiquimod (IMI) cream and ingenol mebutate (IM) gel, in treatment of actinic keratosis (AK).
Participants will be randomized to receive a single IM injection of selected dose of ExPEC10V on Day 1. The ExPEC10V dose used in Cohort 2 will be based on the primary analysis (Day 30) results of Cohort 1.
PURPOSE: To determine how time to surgical debridement and fixation affects infection and complication rate in type I open distal radius fractures by comparing patients treated within 24 hours with those treated >24 hours post-injury.
METHODS: A retrospective review identified 62 patients who sustained a type I open distal radius fracture that was treated surgically. Patients were stratified into groups based on time to surgical intervention. An additional analysis was performed on patients with an isolated type I open distal radius fracture treated as an inpatient or outpatient. The primary outcome measure was infection rate. Secondary outcome measures were complications, reoperations, and readmissions.
RESULTS: Thirty-eight patients underwent surgery ≤24 hours post-injury at an average of 14 hours. Twenty-four patients underwent surgery >24 hours post-injury at an average of 72 hours. There were a total of 9 complications in 8 patients (14.5%). The overall infection rate was 1.6%, with only 1 deep infection occurring in the group treated ≤24 hours post-injury. There were 7 reoperations (11.3%) and 1 readmission (1.6%). No differences were found between groups in any outcome measure. In the 27 patients with an isolated fracture, there were no differences in any outcome measure when treated as an inpatient or outpatient.
CONCLUSIONS: We suggest that type I open distal radius fractures could be safely treated surgically >24 hours post-injury without increased risk of infection.
FIELD: medicine, oncology, protein chemistry. SUBSTANCE: retroplacental or abortive serum is tested, frozen and frozen out before onset of alpha-fetoprotein isolation followed by centrifugation. Then ammonium sulfate saturated solution is added to supernatant up to 30% of saturation, centrifuged again, crystalline ammonium sulfate is added to supernatant up to 70% of saturation and centrifuged. Obtained precipitate is dissolved in 10 mM sodium phosphate solution, pH 7.3, dialyzed, centrifuged and purified by affinity, ion-exchange and gel-exclusive chromatography followed by concentrating the purified alpha-fetoprotein to 1.5-5.0 mg/ml. Then the conjugation of alpha-fetoprotein (concentration is 1.5-2.0 mg/ml) with 2,3,7,8-tetrachlorodibenzo-p-dioxine dissolved in dioxane is carried out followed by addition of mannitol up to the concentration 5%, lyophilic drying, hermetic package under inert gas atmosphere and storage at -70 C. Invention can be used in chemotherapy of oncological patients. EFFECT: enhanced effectiveness of suppression of cancer cells proliferation of hormone-dependent organs and tissues. 1 cl, 1 ex
FIELD: medicine, food industry, veterinary science. SUBSTANCE: method involves addition of bacterium culture Bifidobacterium bifidum sowing dose to nutrient medium containing base nutrient medium with additions of cysteine hydrochloride, baker's yeast autolyzate, D-(-)-lactose, ascorbic acid and milk pancreatic hydrolyzate. Sterile milk at dry residue content 11-14% is used as nutrient medium base. Culturing is carried out to biological titer of bifidobacteria concentrate (0.8-1.0) x 10 10  CFU/ml, not less, at acidity 100-120 degrees T followed by cooling and package of ready product. For bifidokefir preparing milk is subjected for thermic treatment, cooled to fermentation point; kefir ferment and bifidobacterium biomass were added successively to milk followed by fermentation, cooling and package of ready product. For bifidomilk preparing milk is subjected for thermic treatment, cooled to 18-25 C and bifidobacterium biomass is added to milk followed by stirring, cooling and package of ready product. Bacterium concentrate of Bifidobacterium bifidum at biotiter (0.8-1.0) x 10 10  CFU/ml is used as bifidobacterium biomass at the following ratio of components, wt.-%: bifidobacterium concentrate 0.05-0.2, and milk - the rest to 100%. EFFECT: improved method of preparing. 4 cl, 3 tbl
PURPOSE: To obtain a medicinal agent having synergistic effect in hypertension therapy, by containing a calcium channel blocker and a calcium compound. CONSTITUTION: This medicinal agent, which contains a calcium channel blocker (e.g. nifedipine, verapamil) and a calcium compound (e.g. calcium carbonate), is obtained by formulating these active ingredients with a pharmaceuticallypermissible vehicle followed by pharmaceutical manufacturing by a conventional means. The amount of the calcium channel blocker to be formulated is such as to be enough to depress block pressure by 10-50%, that is, for the weight ratio of the calcium channel blocker to calcium compound (nifedipine/calcium carbonate) is (1:400) to (1:17), while verapamil/calcium carbonate (1:22) to (1:3). This medicinal agent is prepared into a form of tablets or capsules.
Placebo (subcutaneous depot) 1.0 mL, subcutaneous injection once monthly, six months treatment. If down-titration is required, 0.5 mL dose is available.
For oral inhalation only

  * Shake well before use.  

  * Avoid spraying in the eyes.  

  * Prime the inhaler before using for the first time and when the inhaler has not been used for more than 3 days by releasing 4 test sprays into the air, away from the face.  

  * To maintain proper use of Levalbuterol tartrate HFA inhalation aerosol, it is critical to wash the actuator with warm water and air-dry thoroughly at least once a week. The inhaler may cease to deliver levalbuterol tartrate if not properly cleaned and dried thoroughly. Keep the plastic actuator clean to prevent medication build-up and blockage. If the actuator becomes blocked with levalbuterol tartrate, wash the actuator to remove the blockage
  * The canister is fitted with a dose indicator, which indicates how many inhalations remain. The dose indicator display will move after every tenth actuation. When nearing the end of the usable inhalations, the color behind the number in the dose indicator window changes to red. Discard the inhaler when the dose indicator display window shows zero, corresponding to the use of 200 actuations.
Participants complete exercise program including aerobic and resistance exercises over 60 minutes 3 times per week for 12 weeks. Exercise is supervised all 3 times during weeks 1-2. During weeks 3-12, exercise is supervised 2 times a week, with home-based coaching for an additional 60 minutes a week.
Antibiotic-associated diarrhea (AAD) is diarrhea caused by disturbances in intestinal microbiota and metabolism following inappropriate use of antibiotics. With the over-reliance on antibiotics, the incidence of AAD is increasing worldwide. Recently, the role of probiotics and prebiotic preparations in the prevention and treatment of AAD has received increasing attention. Various prebiotics can not only reduce the incidence of AAD, but also effectively shorten the course of the disease and alleviate the symptoms. Notably, many polysaccharides derived from plants and fungi are a class of biologically active and rich prebiotics with great potential to alleviate AAD. Therefore, this review aims to summarize the latest research on natural product polysaccharides to alleviate antibiotic-associated diarrhea by modulating the gut microbiota. It provides a theoretical basis for exploring the mechanism of natural product modulation of gut microbiota to alleviate AAD, and provides a reference for further development of active prebiotics.
Post-stroke lower limb spasticity disrupts balance and walking, often resulting in decreased walking speed, increased wheelchair use, and the need for caregiver assistance. Various approaches are utilized in spasticity management, including physical therapy, splinting, oral medications, chemical neurolysis, and surgical interventions. Laser therapy is a non-invasive, painless modality used in physiotherapy units, with a low incidence of side effects. Laser therapy has been shown to reduce muscle fatigue and increase peak torque (muscle strength) when applied before exercise. The use of high-intensity laser therapy in physiotherapy protocols has become increasingly common in recent years. Studies suggest that it enhances healing in tendons and ligaments, prevents fibrosis development, increases local blood flow and tissue regeneration, and reduces edema and pain. The aim of this study is to investigate the effectiveness of high-intensity laser therapy for treating plantar flexor muscle spasticity in subacute and chronic stroke patients, focusing on its impact on spasticity, joint range of motion, pain, muscle thickness, functional ambulation, and quality of life.
Subjects will collect spectral raman data on P0.2 for minimum 10 hours per day with a maximum of 15 minutes between each measurement for 5 days distributed over a time period of 10 days. Spectral data will be compared to standard BG and/or FGM measurements.